nodes	percent_of_prediction	percent_of_DWPC	metapath
Lithium—Myxoedema—Thalidomide—leprosy	0.0968	0.2	CcSEcCtD
Lithium—GRIA3—nerve—leprosy	0.0878	0.191	CbGeAlD
Lithium—GSK3B—nerve—leprosy	0.076	0.165	CbGeAlD
Lithium—Creatinine low—Thalidomide—leprosy	0.0364	0.0751	CcSEcCtD
Lithium—Blood creatinine decreased—Thalidomide—leprosy	0.0333	0.0687	CcSEcCtD
Lithium—GSK3B—eye—leprosy	0.0318	0.069	CbGeAlD
Lithium—IMPA2—skin of body—leprosy	0.0282	0.0612	CbGeAlD
Lithium—GSK3A—eye—leprosy	0.0276	0.06	CbGeAlD
Lithium—IMPA1—testis—leprosy	0.0237	0.0514	CbGeAlD
Lithium—IMPA1—nervous system—leprosy	0.0232	0.0505	CbGeAlD
Lithium—IMPA2—tendon—leprosy	0.0214	0.0466	CbGeAlD
Lithium—GRIA3—testis—leprosy	0.0201	0.0437	CbGeAlD
Lithium—GRIA3—nervous system—leprosy	0.0197	0.0429	CbGeAlD
Lithium—GSK3A—tendon—leprosy	0.0183	0.0398	CbGeAlD
Lithium—Albuminuria—Dapsone—leprosy	0.0182	0.0376	CcSEcCtD
Lithium—IMPA2—testis—leprosy	0.0177	0.0386	CbGeAlD
Lithium—GSK3B—testis—leprosy	0.0174	0.0379	CbGeAlD
Lithium—GSK3B—nervous system—leprosy	0.0171	0.0372	CbGeAlD
Lithium—GSK3A—testis—leprosy	0.0151	0.0329	CbGeAlD
Lithium—GSK3A—nervous system—leprosy	0.0149	0.0323	CbGeAlD
Lithium—Sexual dysfunction—Thalidomide—leprosy	0.0124	0.0257	CcSEcCtD
Lithium—Psoriasis—Thalidomide—leprosy	0.0111	0.0229	CcSEcCtD
Lithium—Hypothyroidism—Thalidomide—leprosy	0.0109	0.0224	CcSEcCtD
Lithium—Hypercalcaemia—Thalidomide—leprosy	0.01	0.0207	CcSEcCtD
Lithium—Nystagmus—Thalidomide—leprosy	0.00976	0.0201	CcSEcCtD
Lithium—Stupor—Thalidomide—leprosy	0.00934	0.0193	CcSEcCtD
Lithium—Albuminuria—Thalidomide—leprosy	0.00934	0.0193	CcSEcCtD
Lithium—Skin ulcer—Thalidomide—leprosy	0.00895	0.0185	CcSEcCtD
Lithium—Muscular weakness—Dapsone—leprosy	0.00872	0.018	CcSEcCtD
Lithium—Oliguria—Thalidomide—leprosy	0.00756	0.0156	CcSEcCtD
Lithium—Leukocytosis—Thalidomide—leprosy	0.00742	0.0153	CcSEcCtD
Lithium—Coordination abnormal—Thalidomide—leprosy	0.0071	0.0147	CcSEcCtD
Lithium—GSK3B—Senescence and Autophagy in Cancer—TNFSF15—leprosy	0.0069	0.124	CbGpPWpGaD
Lithium—Depressed level of consciousness—Thalidomide—leprosy	0.00673	0.0139	CcSEcCtD
Lithium—Tinnitus—Dapsone—leprosy	0.00637	0.0132	CcSEcCtD
Lithium—Hypertonia—Thalidomide—leprosy	0.00611	0.0126	CcSEcCtD
Lithium—Vision blurred—Dapsone—leprosy	0.00561	0.0116	CcSEcCtD
Lithium—Vertigo—Dapsone—leprosy	0.00535	0.011	CcSEcCtD
Lithium—GSK3A—T-Cell Receptor and Co-stimulatory Signaling—CD8A—leprosy	0.0053	0.0954	CbGpPWpGaD
Lithium—Lethargy—Thalidomide—leprosy	0.00516	0.0107	CcSEcCtD
Lithium—Ataxia—Thalidomide—leprosy	0.00476	0.00982	CcSEcCtD
Lithium—Dehydration—Thalidomide—leprosy	0.00471	0.00971	CcSEcCtD
Lithium—Dry skin—Thalidomide—leprosy	0.00464	0.00957	CcSEcCtD
Lithium—Muscular weakness—Thalidomide—leprosy	0.00446	0.00921	CcSEcCtD
Lithium—Erectile dysfunction—Thalidomide—leprosy	0.00403	0.00831	CcSEcCtD
Lithium—Weight increased—Thalidomide—leprosy	0.00398	0.00822	CcSEcCtD
Lithium—Gastrointestinal pain—Dapsone—leprosy	0.00397	0.0082	CcSEcCtD
Lithium—Weight decreased—Thalidomide—leprosy	0.00396	0.00817	CcSEcCtD
Lithium—Hyperglycaemia—Thalidomide—leprosy	0.00394	0.00814	CcSEcCtD
Lithium—GSK3B—T-Cell Receptor and Co-stimulatory Signaling—CD8A—leprosy	0.00392	0.0705	CbGpPWpGaD
Lithium—Drowsiness—Thalidomide—leprosy	0.0039	0.00805	CcSEcCtD
Lithium—Body temperature increased—Dapsone—leprosy	0.00384	0.00793	CcSEcCtD
Lithium—Abdominal pain—Dapsone—leprosy	0.00384	0.00793	CcSEcCtD
Lithium—Bradycardia—Thalidomide—leprosy	0.00356	0.00736	CcSEcCtD
Lithium—Tinnitus—Thalidomide—leprosy	0.00326	0.00674	CcSEcCtD
Lithium—Arrhythmia—Thalidomide—leprosy	0.00313	0.00645	CcSEcCtD
Lithium—Alopecia—Thalidomide—leprosy	0.00309	0.00638	CcSEcCtD
Lithium—Vomiting—Dapsone—leprosy	0.00309	0.00638	CcSEcCtD
Lithium—Headache—Dapsone—leprosy	0.00304	0.00628	CcSEcCtD
Lithium—Flatulence—Thalidomide—leprosy	0.003	0.0062	CcSEcCtD
Lithium—Dysgeusia—Thalidomide—leprosy	0.00298	0.00616	CcSEcCtD
Lithium—Nausea—Dapsone—leprosy	0.00289	0.00596	CcSEcCtD
Lithium—Vision blurred—Thalidomide—leprosy	0.00287	0.00593	CcSEcCtD
Lithium—Tremor—Thalidomide—leprosy	0.00285	0.00589	CcSEcCtD
Lithium—GSK3A—T-Cell Receptor and Co-stimulatory Signaling—IL2—leprosy	0.0028	0.0504	CbGpPWpGaD
Lithium—Agitation—Thalidomide—leprosy	0.0028	0.00578	CcSEcCtD
Lithium—Angioedema—Thalidomide—leprosy	0.00278	0.00575	CcSEcCtD
Lithium—Vertigo—Thalidomide—leprosy	0.00274	0.00565	CcSEcCtD
Lithium—Syncope—Thalidomide—leprosy	0.00273	0.00564	CcSEcCtD
Lithium—Loss of consciousness—Thalidomide—leprosy	0.00268	0.00553	CcSEcCtD
Lithium—Convulsion—Thalidomide—leprosy	0.00264	0.00545	CcSEcCtD
Lithium—Arthralgia—Thalidomide—leprosy	0.00259	0.00536	CcSEcCtD
Lithium—Discomfort—Thalidomide—leprosy	0.00256	0.00529	CcSEcCtD
Lithium—Dry mouth—Thalidomide—leprosy	0.00254	0.00524	CcSEcCtD
Lithium—Confusional state—Thalidomide—leprosy	0.00251	0.00518	CcSEcCtD
Lithium—Oedema—Thalidomide—leprosy	0.00249	0.00513	CcSEcCtD
Lithium—Shock—Thalidomide—leprosy	0.00245	0.00505	CcSEcCtD
Lithium—Anorexia—Thalidomide—leprosy	0.00237	0.00489	CcSEcCtD
Lithium—Hypotension—Thalidomide—leprosy	0.00232	0.0048	CcSEcCtD
Lithium—Musculoskeletal discomfort—Thalidomide—leprosy	0.00227	0.00468	CcSEcCtD
Lithium—Somnolence—Thalidomide—leprosy	0.00221	0.00456	CcSEcCtD
Lithium—Dyspepsia—Thalidomide—leprosy	0.00219	0.00452	CcSEcCtD
Lithium—GSK3A—IL-5 Signaling Pathway—IL2—leprosy	0.00217	0.039	CbGpPWpGaD
Lithium—Decreased appetite—Thalidomide—leprosy	0.00216	0.00446	CcSEcCtD
Lithium—Fatigue—Thalidomide—leprosy	0.00214	0.00443	CcSEcCtD
Lithium—GSK3B—T-Cell Receptor and Co-stimulatory Signaling—IL2—leprosy	0.00207	0.0372	CbGpPWpGaD
Lithium—Feeling abnormal—Thalidomide—leprosy	0.00205	0.00423	CcSEcCtD
Lithium—Gastrointestinal pain—Thalidomide—leprosy	0.00203	0.0042	CcSEcCtD
Lithium—Abdominal pain—Thalidomide—leprosy	0.00197	0.00406	CcSEcCtD
Lithium—Body temperature increased—Thalidomide—leprosy	0.00197	0.00406	CcSEcCtD
Lithium—Asthenia—Thalidomide—leprosy	0.00178	0.00368	CcSEcCtD
Lithium—Diarrhoea—Thalidomide—leprosy	0.0017	0.00351	CcSEcCtD
Lithium—Dizziness—Thalidomide—leprosy	0.00164	0.00339	CcSEcCtD
Lithium—GSK3B—IL-5 Signaling Pathway—IL2—leprosy	0.0016	0.0288	CbGpPWpGaD
Lithium—Vomiting—Thalidomide—leprosy	0.00158	0.00326	CcSEcCtD
Lithium—Rash—Thalidomide—leprosy	0.00157	0.00324	CcSEcCtD
Lithium—IMPA2—Metabolism—SDHD—leprosy	0.00157	0.0282	CbGpPWpGaD
Lithium—Dermatitis—Thalidomide—leprosy	0.00157	0.00323	CcSEcCtD
Lithium—Headache—Thalidomide—leprosy	0.00156	0.00322	CcSEcCtD
Lithium—Nausea—Thalidomide—leprosy	0.00148	0.00305	CcSEcCtD
Lithium—IMPA1—Metabolism—SDHD—leprosy	0.0014	0.0251	CbGpPWpGaD
Lithium—GSK3B—TWEAK Signaling Pathway—TNF—leprosy	0.00112	0.0202	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—RIPK2—leprosy	0.00112	0.0202	CbGpPWpGaD
Lithium—GSK3B—Glucocorticoid receptor regulatory network—IFNG—leprosy	0.00101	0.0182	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—CYLD—leprosy	0.000993	0.0179	CbGpPWpGaD
Lithium—GSK3B—Cardiac Hypertrophic Response—TNF—leprosy	0.000904	0.0163	CbGpPWpGaD
Lithium—GSK3B—Glucocorticoid receptor regulatory network—IL2—leprosy	0.000902	0.0162	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—PARK2—leprosy	0.000843	0.0152	CbGpPWpGaD
Lithium—GSK3B—Senescence and Autophagy in Cancer—IFNG—leprosy	0.000832	0.015	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—RIPK2—leprosy	0.000829	0.0149	CbGpPWpGaD
Lithium—GSK3B—Corticotropin-releasing hormone—IL2—leprosy	0.000822	0.0148	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—CYLD—leprosy	0.000733	0.0132	CbGpPWpGaD
Lithium—GSK3B—Alzheimers Disease—TNF—leprosy	0.000677	0.0122	CbGpPWpGaD
Lithium—GSK3B—MicroRNAs in cardiomyocyte hypertrophy—TNF—leprosy	0.000644	0.0116	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—RIPK2—leprosy	0.00064	0.0115	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—TLR2—leprosy	0.00064	0.0115	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—PARK2—leprosy	0.000623	0.0112	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—RIPK2—leprosy	0.000614	0.011	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—NOD2—leprosy	0.00058	0.0104	CbGpPWpGaD
Lithium—GSK3A—Immune System—CYLD—leprosy	0.000578	0.0104	CbGpPWpGaD
Lithium—GSK3A—Immune System—PARK2—leprosy	0.000511	0.00919	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—TLR2—leprosy	0.000473	0.0085	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—RIPK2—leprosy	0.000473	0.0085	CbGpPWpGaD
Lithium—GSK3A—Disease—SLC11A1—leprosy	0.000472	0.00849	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—CD40LG—leprosy	0.000471	0.00847	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—CD8A—leprosy	0.000465	0.00837	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—RIPK2—leprosy	0.000454	0.00816	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—TNF—leprosy	0.000452	0.00813	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—NOD2—leprosy	0.000428	0.00771	CbGpPWpGaD
Lithium—GSK3B—Immune System—CYLD—leprosy	0.000427	0.00768	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—HLA-DRB1—leprosy	0.000379	0.00682	CbGpPWpGaD
Lithium—GSK3B—Immune System—PARK2—leprosy	0.000378	0.00679	CbGpPWpGaD
Lithium—GSK3A—Immune System—RIPK2—leprosy	0.000373	0.0067	CbGpPWpGaD
Lithium—GSK3A—Immune System—TLR2—leprosy	0.000373	0.0067	CbGpPWpGaD
Lithium—GSK3B—Disease—SLC11A1—leprosy	0.000349	0.00627	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—CD40LG—leprosy	0.000348	0.00626	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—CD8A—leprosy	0.000344	0.00619	CbGpPWpGaD
Lithium—GSK3A—Immune System—NOD2—leprosy	0.000338	0.00607	CbGpPWpGaD
Lithium—GSK3A—Immune System—CD40LG—leprosy	0.000286	0.00514	CbGpPWpGaD
Lithium—GSK3A—Immune System—CD8A—leprosy	0.000282	0.00508	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—HLA-DRB1—leprosy	0.00028	0.00504	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—CD4—leprosy	0.000278	0.00501	CbGpPWpGaD
Lithium—GSK3B—Immune System—RIPK2—leprosy	0.000275	0.00495	CbGpPWpGaD
Lithium—GSK3B—Immune System—TLR2—leprosy	0.000275	0.00495	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—CD4—leprosy	0.000267	0.00481	CbGpPWpGaD
Lithium—GSK3B—Immune System—NOD2—leprosy	0.00025	0.00449	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—RIPK2—leprosy	0.000241	0.00433	CbGpPWpGaD
Lithium—GSK3A—Immune System—HLA-DRB1—leprosy	0.00023	0.00413	CbGpPWpGaD
Lithium—GSK3B—Immune System—CD40LG—leprosy	0.000211	0.00379	CbGpPWpGaD
Lithium—GSK3B—Immune System—CD8A—leprosy	0.000209	0.00375	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—CD4—leprosy	0.000206	0.0037	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—CD4—leprosy	0.000198	0.00355	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—RIPK2—leprosy	0.000178	0.0032	CbGpPWpGaD
Lithium—GSK3B—Immune System—HLA-DRB1—leprosy	0.00017	0.00306	CbGpPWpGaD
Lithium—GSK3A—Immune System—IFNG—leprosy	0.000168	0.00302	CbGpPWpGaD
Lithium—GSK3A—Immune System—CD4—leprosy	0.000162	0.00292	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—TNF—leprosy	0.000156	0.00281	CbGpPWpGaD
Lithium—GSK3A—Disease—CD4—leprosy	0.00015	0.00269	CbGpPWpGaD
Lithium—GSK3A—Immune System—IL2—leprosy	0.000149	0.00268	CbGpPWpGaD
Lithium—GSK3B—Immune System—IFNG—leprosy	0.000124	0.00223	CbGpPWpGaD
Lithium—GSK3B—Immune System—CD4—leprosy	0.00012	0.00216	CbGpPWpGaD
Lithium—GSK3B—Disease—CD4—leprosy	0.000111	0.00199	CbGpPWpGaD
Lithium—GSK3B—Immune System—IL2—leprosy	0.00011	0.00198	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—IL2—leprosy	9.65e-05	0.00173	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—IL2—leprosy	7.13e-05	0.00128	CbGpPWpGaD
